Neuraxpharm launches ADHD treatment options in Europe

German CNS-focused specialist Neuraxpharm Group announced the launches in Europe of Tuzulby (methylphenidate hydrochloride) prolonged-release chewable tablets and Paxneury (guanfacine) prolonged-release tablets, two differentiated treatments designed to meet the diverse needs of children and adolescents living with attention deficit and hyperactivity disorder (ADHD).

Tuzulby prolonged-release chewable tablets, developed by Tris Pharma and available since December 2025 in Germany, the UK and the Nordic countries, is the first and only once-daily, prolonged-release, chewable methylphenidate tablet for children and adolescents with ADHD in Europe. Indicated for those aged 6-17 years, it is part of a holistic treatment programme for ADHD when remedial measures alone prove insufficient1. It enables flexible, individualised dosing according to the treatment needs and responses of the patient with a convenient chewable format to support treatment adherence. Further launches across Europe are planned in the coming months.

Paxneury, a second-line treatment in ADHD management, launched in September in multiple European countries, is the only prolonged-release guanfacine formulation in Europe to offer a wider spectrum of strengths, with higher doses of 5mg, 6mg, and 7mg launched. Licensed for the treatment of ADHD in children and adolescents aged 6–17 years for whom stimulants are not suitable, not tolerated or are shown to be ineffective, it allows for individualised dosing according to the patient’s response and tolerability and is the first generic prolonged-release guanfacine to reach the European market. It was developed by HealthTech, Neuraxpharm’s R&D center specializing in delivering innovative solutions in the CNS field, like this value-added product.